Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00557401 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD
A Phase 2 study, sponsored by XenoPort.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT00557401: Completed Phase 2 study, sponsored by XenoPort.
NCT00557401 is a Phase 2 study that has completed, run by XenoPort. The registered enrollment target is 156 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00557401, a Phase 2 study, has completed, sponsored by XenoPort.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with symptomatic GERD
Interventions
- DRUG Placebo
- DRUG XP19986 SR3, 20 mg QD
- DRUG XP19986 SR3, 40 mg QD
- DRUG XP19986 SR3, 60 mg QD
- DRUG XP19986 SR3, 30 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
What the finished NCT00557401 record still lists
NCT00557401 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00557401 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00557401 about?
NCT00557401 is a clinical study titled "An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD". To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with symptomatic GERD
What is the current status of trial NCT00557401?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2007-11. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00557401?
The interventions under investigation include: Placebo (DRUG), XP19986 SR3, 20 mg QD (DRUG), XP19986 SR3, 40 mg QD (DRUG), XP19986 SR3, 60 mg QD (DRUG), XP19986 SR3, 30 mg BID (DRUG).
Who is sponsoring clinical trial NCT00557401?
This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00557401's enrollment target sits among peer trials
156 445th of 2000 higher than 1,553 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia